|Venture Round, 11/2008 |
New Enterprise Associates
|Partial Close, 11/2009 ||$357k|
|Debt, 8/2010 |
Lighthouse Capital Partners
ARYx is a product-driven pharmaceutical company with leading expertise and significant intellectual property in the area of retrometabolic drug design. They are focused on improving the safety of oral therapies for chronic disease.